The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
Top Cited Papers
Open Access
- 23 May 2012
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 379 (9834), 2352-2363
- https://doi.org/10.1016/s0140-6736(12)60768-5
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysisThe Lancet, 2012
- Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruitedTrials, 2011
- Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposalTrials, 2010
- A simulation study evaluating approaches to the analysis of ordinal outcome data in randomized controlled trials in traumatic brain injury: results from the IMPACT ProjectClinical Trials, 2010
- Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic reviewThe Lancet Neurology, 2009
- The third international stroke trial (IST-3) of thrombolysis for acute ischaemic strokeTrials, 2008
- Predicting Long-Term Outcome After Acute Ischemic StrokeStroke, 2008
- Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studiesBMJ, 2008
- MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosisThe Lancet, 1991
- Interobserver agreement for the assessment of handicap in stroke patients.Stroke, 1988